Eon Labs to Pay $3.5M for Medicaid False Claims
Eon Labs Inc. will pay the federal government $3.5 million to settle False Claims Act allegations raised in a whistleblower suit relating to drug maker's Nitroglycerin Sustained Release capsules, the Justice Department announced today.
The FDA ruled in 1999 that Nitroglycerin SR had unproven effectiveness and issued a notice to withdraw approval of the drug, which made it no longer legally eligible for Medicaid reimbursements, DOJ said in a media release.
DOJ alleges that from April 1999 through September 2008, Eon submitted false quarterly reports to the government that misrepresented Nitroglycerin SR's status and failed to report that Nitroglycerin SR no longer qualified for Medicaid reimbursements. As a result, DOJ contends, Eon knowingly submitted fraudulent Medicaid claims.
Eon Labs is a subsidiary of Sandoz Inc., which is a subsidiary of Novartis AG.
"This is the first False Claims Act agreement with a drug company that sought to charge the government for less than effective drugs, and it shows that the Department of Justice will pursue those who market such drugs and expect the government to pay for them," said Carmen Ortiz, US Attorney for the District of Massachusetts, in a media release.
- As Medicare Advantage Cuts Loom, Disagreement Over Program's Stability
- Medicare Advantage Carriers See 'No Choice' But to Accept Cuts
- Centralizing the Revenue Cycle Protects the Bottom Line
- Physicians to Appeal 'Docs v. Glocks' Ruling in FL
- CA Fines 8 Hospitals for Medical Errors
- 3 Management Lessons from a Supermarket Debacle
- Doctors Feel Pressure to Accept Risk-based Reimbursement
- Employers Weigh Risks, Benefits of Private Exchanges
- Surgical Checklists Unused in 10% of Hospitals, CMS Data Shows
- Revenue Cycles Get a Boost from Simple JPEG Files